Q4 EPS Estimate for Adherex Technologies Reduced by Analyst

Key Points

• HC Wainwright has revised its Q4 2025 earnings estimate for Adherex Technologies to ($0.01), down from a prior forecast of $0.01, while maintaining a "Buy" rating and a $13 price target.
• The company's recent earnings report showed a loss of ($0.11) per share, which missed the consensus estimate by ($0.05), despite revenue of $9.76 million exceeding expectations.
• Significant insider selling was reported, with Director Rosty Raykov selling 10,000 shares, indicative of potential concerns within the company's direction or performance.

Adherex Technologies Inc. (NASDAQ:FENC - Free Report) - Investment analysts at HC Wainwright decreased their Q4 2025 earnings per share (EPS) estimates for Adherex Technologies in a report released on Thursday, August 21st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.01) for the quarter, down from their prior forecast of $0.01. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Adherex Technologies' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Adherex Technologies' Q1 2026 earnings at $0.07 EPS and Q4 2026 earnings at $0.25 EPS.

Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The company had revenue of $9.76 million during the quarter, compared to the consensus estimate of $9.52 million.

A number of other equities research analysts also recently weighed in on FENC. Zacks Research downgraded Adherex Technologies from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. Wall Street Zen upgraded Adherex Technologies from a "hold" rating to a "buy" rating in a research report on Sunday, August 17th. Finally, Craig Hallum raised their price target on Adherex Technologies from $13.00 to $14.00 and gave the company a "buy" rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $13.33.

Adherex Technologies Stock Up 2.1%

NASDAQ:FENC traded up $0.19 during trading hours on Friday, hitting $8.87. 17,208 shares of the company's stock traded hands, compared to its average volume of 77,229. The firm has a market cap of $246.56 million, a P/E ratio of -21.11 and a beta of 0.40. Adherex Technologies has a 52 week low of $3.96 and a 52 week high of $9.42. The business's fifty day simple moving average is $8.45 and its two-hundred day simple moving average is $7.23.

Institutional Trading of Adherex Technologies

Several large investors have recently bought and sold shares of FENC. AIGH Capital Management LLC bought a new stake in shares of Adherex Technologies in the 1st quarter worth approximately $2,199,000. Solas Capital Management LLC boosted its position in shares of Adherex Technologies by 17.0% in the 4th quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company's stock worth $14,226,000 after purchasing an additional 327,383 shares in the last quarter. Nuveen LLC bought a new stake in shares of Adherex Technologies in the 1st quarter worth approximately $158,000. MetLife Investment Management LLC bought a new stake in shares of Adherex Technologies in the 4th quarter worth approximately $99,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Adherex Technologies in the 4th quarter worth approximately $97,000. 55.51% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Adherex Technologies news, Director Rosty Raykov sold 10,000 shares of Adherex Technologies stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $8.09, for a total transaction of $80,900.00. Following the sale, the director directly owned 55,878 shares of the company's stock, valued at approximately $452,053.02. The trade was a 15.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 31,119 shares of company stock worth $254,546. Insiders own 10.98% of the company's stock.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.